Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 11, 2016, Pages E1419-E1420

  Subbiah, Vivek ^a   Hong, David S ^a   Meric Bernstam, Funda ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CERITINIB; CRIZOTINIB; IPILIMUMAB; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; ROS1 PROTEIN; UNCLASSIFIED DRUG; ANILIDE; ANTINEOPLASTIC AGENT; ONCOPROTEIN; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE;

AGED; ANTINEOPLASTIC ACTIVITY; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DYSPNEA; GAMMA KNIFE RADIOSURGERY; GENE REARRANGEMENT; HUMAN; LETTER; LUNG BIOPSY; MALE; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PHARMACOGENETICS; PRIORITY JOURNAL; THORACOTOMY; THORAX RADIOGRAPHY; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; MOLECULAR MODEL; PHYSIOLOGY;

ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, MOLECULAR; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PYRIDINES;

EID: 84962505302     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1522052113     Document Type: Letter

References (5)

1. Davare MA, et al. (2015) Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Proc Natl Acad Sci USA 112(39):E5381-E5390.
2. Shaw AT, et al. (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371(21):1963-1971.
3. Shen L, Ji HF (2014) Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370(26):2537.
4. Shaw AT, et al. (2014) Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370(13):1189-1197.
5. Kang BP, et al. (2015) The signature program: Bringing the protocol to the patient. Clin Pharmacol Ther 98(2):124-126.